<DOC>
	<DOC>NCT01578499</DOC>
	<brief_summary>This is a Randomized, Open-Label, Phase 3 trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma</brief_summary>
	<brief_title>A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<mesh_term>Lymphoma, Primary Cutaneous Anaplastic Large Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Voluntary consent form Male or female patients 18 years or older with diagnosis of MF or pcALCL Patients with pcALCL who have received prior radiation therapy or at least 1 prior systemic therapy; patients with MF who have received at least 1 prior systemic therapy Histologically confirmed CD30+ disease by central laboratory assessment and pathology review Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2 Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject Male patients who agree to practice effective barrier contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject Clinical laboratory values as specified in protocol A concurrent diagnosis of systemic ALCL,other non Hodgkin lymphoma(excluding LyP) or Sezary syndrome or B2 disease Patients with cardiovascular conditions specified in protocols Patients with history of another primary malignancy not in remission for at least 3 years Known active cerebral/meningeal disease, HIV infection, hepatitis B or Hepatitis C infection Oral retinoid therapy for any indication within 3 weeks of study entry Corticosteroid therapy within 3 weeks or immunosuppressive chemotherapy or any antibodydirected or immunoglobulinbased immune therapy (eg, immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first dose of study drug Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 of any cycle Previous receipt of brentuximab vedotin Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria. Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>brentuximab vedotin</keyword>
	<keyword>ALCANZA</keyword>
</DOC>